HyperAIHyperAI

Command Palette

Search for a command to run...

GeneBench-Pro: 유전체학, 정량 생물학 및 중개 생의학에서의 다단계 통계적 추론 평가

Jeremy Li Andrew Ho

초록

GeneBench-Pro는 더 넓은 범위의 도메인에 걸쳐 더 어려운 문제들로 구성된 GeneBench의 확장 및 개선된 버전이다. GeneBench-Pro는 유전체학, 정량 생물학 및 중개 생의학에서 현실적인 다단계 과학적 분석을 수행하는 AI 에이전트를 위한 벤치마크로, 하류의 과학적 또는 중개적 결정을 좌우할 결론을 도출해야 하는 컴퓨터 생명과학자들이 직면하는 실제 문제의 복잡성을 포착하고자 한다. 이 벤치마크는 유전체학 중심의 핵심을 바탕으로 10개의 주요 도메인과 21개의 말단 하위 도메인에 걸쳐 실질적으로 직접적인 관련성이 있는 수량을 목표로 하는 129개의 평가로 구성된다. GeneBench와 유사하게, 각 문제는 에이전트에게 간략한 맥락, 목표 추정량, 그리고 그 외에는 최소한의 지침만을 제공하며; 에이전트는 이후 올바른 분석 워크플로우를 식별하고 실행하여 정답에 도달하기 위해 여러 개의 종속적인 의사 결정 지점, 즉 그럴듯한 잘못된 선택이 하류 분석을 바꾸는 실질적인 추론 분기점들을 탐색해야 한다. GeneBench 대비, GeneBench-Pro는 29개의 새로운 문제를 추가하고 3개를 제거했으며, 중복되는 나머지 100개 문제 중 54개에 대해 상당히 재설계된 버전을 도입했다. 129개 문제 중 82개는 외부 도메인 전문가에 의해 검토되었으며, 그 결과로 프롬프트/데이터 수정과 목표가 충분히 식별되지 않는 문제들의 재설계가 이루어졌다. 외부 검토를 거친 10개 문제는 공개되었고, 50개의 비공개 문제는 독립적인 제3자 모델 벤치마킹을 위해 Artificial Analysis에 제공되었으며, 나머지는 내부 비공개 문제로 보유된다. 전체 129개 문제 모음에 대한 평가에서, GPT-5.6 Sol은 최대 추론 수준에서 28.7%의 평가 수준 통과율을 달성했고, 별도로 보고된 GPT Pro 실행에서 GPT-5.6 Sol Pro는 31.5%를 달성했다. GPT-5.5는 12.0%, GPT-5.4는 8.9%를 달성했으며, 가장 강력한 non-GPT 기준 모델인 Claude Opus 4.8은 16.0%를 달성했다. GeneBench에서와 같이, 모델들은 종종 워크플로의 상당 부분을 완료하지만, 국소적 진단 신호를 식별하면서도 그 함의를 해당 분석 결정에 전파하지 못함으로써 알아차림과 행동 사이에 일관된 격차를 보인다. 그 결과, 모델들은 종종 잘못된 추정량을 선택하거나 초기에는 그럴듯하지만 잘못된 분석 경로를 고수한다. 따라서 GeneBench-Pro는 여전히 신뢰할 수 없는 장기적 생물학적 추론이라는 떠오르는 능력을 측정한다.

One-sentence Summary

OpenAI introduces GeneBench-Pro, an expanded benchmark of 129 multi-stage scientific problems spanning 10 primary domains and 21 terminal subdomains in genomics, quantitative biology, and translational biomedicine that forces AI agents to navigate multiple dependent inferential forks where a plausible wrong choice changes the downstream analysis; models such as GPT-5.6 Sol Pro reach a 31.5%31.5\%31.5% pass rate but consistently exhibit a gap between noticing local diagnostic signals and acting on them, often selecting wrong estimators and persisting on initially plausible but incorrect analysis paths, underscoring the unreliability of long-horizon biological reasoning.

Key Contributions

  • GeneBench-Pro is a benchmark of 129 multi-stage scientific analysis problems across genomics, quantitative biology, and translational biomedicine, with 82 problems reviewed by external domain experts to improve target identifiability and difficulty.
  • Evaluations of over 60 model configurations show that GPT‑5.6 Sol reaches a pass rate of 28.7%, GPT‑5.6 Sol Pro reaches 31.5%, and models exhibit a gap where local diagnostic signals are detected but not propagated to correct analysis decisions.
  • The benchmark is released in a stratified manner: 10 public problems, 50 held-out problems for third-party benchmarking by Artificial Analysis, and an internal holdout.

Introduction

Recent advances in AI agents have shown rapid progress in software engineering and long-horizon tasks, and genomic benchmarks have begun to move from simple knowledge tests toward more realistic biological workflows. However, the open-ended, multi-stage analyses that researchers routinely perform (where a wrong choice at any step can derail the entire conclusion) remain largely unexamined by existing evaluations. The authors introduce GeneBench‑Pro, a substantially hardened and expanded benchmark of 129 problems across genomics, quantitative biology, and translational biomedicine. Each problem requires an agent to navigate multiple dependent decision points with minimal guidance, reflecting the “notice‑act” gap that distinguishes expert from novice reasoning. By providing a tiered public release and evaluating over 60 model configurations, GeneBench‑Pro reveals that even frontier models struggle to reliably close the inferential loop, offering a precise measure of an emerging, high‑impact capability for automating scientific discovery.

Experiment

GeneBench-Pro evaluates frontier models on long-horizon, multi-stage genomic analyses within a containerized Linux environment without internet, using rigorous binary grading that requires correct final answers across all decision points. The benchmark reveals that current models can detect data irregularities and complete intermediate steps, yet they consistently fail to close the "notice-act" inferential loop needed for reliable end-to-end performance, a pattern that resembles expert-novice differences in scientific problem solving. This qualitative gap underscores that despite rapid progress, substantial capability advances in planning, self-revision, and uncertainty-aware control are still needed before models can automate the kinds of analyses that currently demand expert scientists, a goal with transformative potential for accelerating discovery.

GeneBench-Pro imposes design constraints that keep the scientific endpoint identifiable while preserving realistic ambiguity. The framework requires a recoverable ground truth, a single defensible answer supported by empirical constraints, and a clear numerical gap between correct and incorrect solutions, thereby avoiding common failures like unrecoverable parameters, underspecification, and grading artifacts. Problem specification rules further ensure that prompts define the scientific question without dictating the analysis method and that quality control thresholds do not introduce arbitrary evaluation outcomes. Agents are evaluated on quantities actually recoverable from the provided data, not on hidden data-generating parameters, so correct analyses are not wrongly penalized due to sampling variation. Each task supports exactly one defensible answer because the data or prompt includes empirical constraints that reasonably exclude alternative approaches, preventing the evaluation from measuring workflow preference instead of reasoning. Plausible but incorrect analyses and shortcut methods fail by clear margins in an ablation suite, ensuring that wrong solutions are not mistakenly graded as correct. Prompts specify the scientific question and the target estimand without prescriptive instructions, keeping the focus on open-ended reasoning rather than recipe-following. Quality control requirements use thresholds where nearby reasonable values produce the same graded outcome, so the benchmark measures recognition of qualitative problems rather than sensitivity to arbitrary cutoffs.

External review of benchmark problems uncovered several types of issues that prompted revisions to improve clarity and scientific rigor. Common adjustments included refining underspecified or ambiguous prompts, aligning grading with defensible alternative methods, updating ground truth to match realizable data, and fixing method implementations that did not match their stated task. Problems where a defensible alternative method existed, such as the admixture task where posterior-weighted ancestry fractions were scientifically reasonable, were updated to accept those alternatives rather than requiring a hard-call result. A genetic correlation benchmark was found to be grading an ad hoc LD-score estimator instead of true LDSC, and the reference implementation was corrected to match the method it purported to evaluate. When ground truth was not recoverable under the original prompt, like the dynamic pharmacogenomic treatment response, the benchmark was realigned to use the data-generating process's realized data and to make validator target and nuisance specifications explicit. An ambiguous prompt for a somatic target activation problem left room for interpreting high copy number without structural variant involvement, so the solver-facing materials were clarified by adding wording that specifies the causal structural variant mechanism.

GPT-5.6 Sol consistently recognizes and acts on subtle data complexities that GPT-5.5 overlooks or handles with simpler, less appropriate methods. Across pharmacogenomic survival, cell-type heritability, and peptide pQTL tasks, GPT-5.6 Sol correctly adjusts for time-varying confounding, reference-panel quality, and dose-response discordance, leading to more reliable analytical decisions. For pharmacogenomic time-to-event data, GPT-5.6 Sol used a marginal structural Cox model with stabilized inverse-probability weights to address treatment-confounder feedback, while GPT-5.5 applied a conventional counting-process Cox model that did not account for this feedback. When selecting an LD-score reference panel, GPT-5.6 Sol applied stricter quality filters including imputation-quality and chi-squared thresholds, yielding a refined SNP set, whereas GPT-5.5 chose the panel solely by allele-frequency concordance after basic filters. In the bridge-calibrated pQTL analysis, GPT-5.6 Sol identified peptides with discordant dose-response slopes and excluded them before averaging, while GPT-5.5 simply averaged all six peptides, including those with inconsistent patterns.

The GeneBench-Pro framework enforces design constraints that ensure each task has a single defensible ground truth answer and that grading isolates scientific reasoning rather than workflow habits, with failures designed to clearly separate correct from incorrect solutions. External review and revision cycles refined benchmark prompts and validator logic to eliminate ambiguity and confirmed that real-world complexities do not compromise grading reliability. Comparative testing showed that GPT-5.6 Sol consistently applied more appropriate statistical corrections and quality filters to handle subtle data confounds, whereas GPT-5.5 defaulted to simpler methods, demonstrating the benchmark's ability to detect meaningful differences in analytical reasoning.


AI로 AI 구축

아이디어에서 출시까지 — 무료 AI 코코딩, 즉시 사용 가능한 환경, 최적의 GPU 가격으로 AI 개발을 가속화하세요.

AI 협업 코딩
바로 사용 가능한 GPU
최적의 가격

HyperAI Newsletters

최신 정보 구독하기
한국 시간 매주 월요일 오전 9시 에 이번 주의 최신 업데이트를 메일로 발송합니다
이메일 서비스 제공: MailChimp